• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lineage Cell Therapeutics Inc (NY: LCTX )

    0.9083 +0.0380 (+4.37%)
    Official Closing Price Updated: 8:00 PM EDT, Aug 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 423,065
    Open 0.8700
    Bid (Size) 0.8710 (11)
    Ask (Size) 0.9100 (70)
    Prev. Close 0.8703
    Today's Range 0.8621 - 0.9083
    52wk Range 0.7665 - 1.560
    Shares Outstanding 174,986,671
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q2 2024
    LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -16.67%
    -16.67%
    1 Month
    -10.95%
    -10.95%
    3 Month
    -13.50%
    -13.50%
    6 Month
    -14.31%
    -14.31%
    1 Year
    -33.21%
    -33.21%

    More News

    Read More
    Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Cell Therapeutics: Q4 Earnings Insights
    Via Benzinga
    A Preview Of Lineage Cell Therapeutics's Earnings
    Via Benzinga
    Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage to Present at 2024 BIO International Convention
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    LCTX Stock Earnings: Lineage Cell Therapeutics Meets EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Announces Changes to Board of Directors
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Earnings Scheduled For March 7, 2024
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
    From Lineage Cell Therapeutics, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.